New research is being presented at TCT 2014, the Transcatheter Cardiovascular Therapeutics annual meeting, from September 13 to 17, in Washington, DC.
Meeting Highlights
Embolic Protection During TAVI
Comparing TAVR to Surgery in Intermediate-Risk Patients
News From TCT 2014
Cap and Lead Pelvic Drape Reduce Radiation Exposure to Operators in PCI
No MACE Benefit With Prasugrel in ACS
“Sham” Renal Denervation Defended
Six Months of DAPT Offers SECURITY in Low-Risk PCI
PFO Closure Fails Anew in Migraine
FDA Town Hall Paves Way for New Approval Strategies
Renal Denervation Misses in Mildly Hypertensive Patients
Female Interventionalists ‘Very Rare,’ Work in Isolation
No Harm, No Foul With Triple Therapy
Light From BRIGHT: More Fuel for Bivalirudin-Heparin Debate
Reassuring Data on Use of DAPT and Anticoagulation
Rx for Bifurcation Lesions — Hold the Stenting
Bioresorbable Scaffold Safe But Not Spectacular
Dead or Treading Water: Experts Debate Future of Renal Denervation for Resistant Hypertension
No Deaths With Mild/Moderate Paravalvular Leaks: CoreValve Extreme Risk at Two Years
St Jude Issues Worldwide ‘Pause’ on Portico TAVR Implants
CoreValve TAVR Ups Survival, Has $$$ Value
Sapien Valve Survival Benefit Durable at 5 Years
Vascular-Closure Devices as Good as Hands-on After Diagnostic Coronary Angiography
TAVR Deaths at Five Years in PARTNER: Sobering and Remarkable
DC Meeting Highlights Iterative Change
More From TCT 2014
Hillary Clinton Keynote Address
Visual Interactive Technology Center
Late-Breaking Clinical Trials and First Report Investigations
Nurse & Technologist Symposium
